膠囊內視鏡市場按產品類型、內視鏡模式、年齡層、應用、分銷管道和最終用戶分類－2025-2030 年全球預測

膠囊內視鏡市場預計將在 2024 年達到 5.0212 億美元，複合年成長率為 8.01%，到 2025 年將達到 5.4109 億美元，到 2030 年將達到 7.9739 億美元。

主要市場統計數據
基準年2024年	5.0212億美元
預計2025年	5.4109億美元
預測年份 2030	7.9739億美元
複合年成長率（%）	8.01%

探索膠囊內視鏡技術在重新定義非侵入性胃腸診斷和改善患者預後的變革作用

膠囊內視鏡代表了胃腸道診斷領域的突破性創新，它用一種只需吞服的設備取代了傳統的侵入性內視鏡操作。膠囊內視鏡配備高解析度影像感測器，外觀隱蔽，為臨床醫生提供了前所未有的途徑，能夠深入觀察小腸深處先前難以觀察到的區域。因此，與傳統內視鏡相比，患者的不適感和風險更低，有望提高需要定期接受胃腸檢查的患者的遵從率。

確定影響膠囊內視鏡領域並推動全球胃腸成像創新的關鍵技術和監管變化

突破性的技術進步在膠囊內視鏡領域取得了前所未有的變革，模糊了診斷與數據主導決策之間的界線。近期推出的超高解析度成像晶片帶來了前所未有的清晰度，使得以前難以察覺的細微黏膜病變得以檢測。同時，電源管理技術的進步延長了膠囊的電池壽命，使其能夠延長胃腸道的傳輸時間，並實現從食道到結腸的全面可視化。

評估2025年美國關稅調整對全球膠囊內視鏡供應鏈和市場動態的累積影響

2025年美國重新徵收關稅為膠囊內視鏡供應鏈帶來了新的挑戰，促使相關人員重新評估籌資策略和成本結構。先前依賴從主要製造地進口零件的設備製造商，如今正面臨專用影像感測器、微電池單元和無線傳輸模組關稅上調的挑戰。這導致製造成本上升，迫使製造商尋找替代供應商或建立策略夥伴關係關係，以緩解關稅帶來的價格上漲壓力。

揭示產品變體、內視鏡模式、年齡層、臨床應用、分銷管道和最終用戶類別的關鍵細分洞察

全面的細分分析揭示了不同產品組合和臨床環境如何影響市場成長的清晰模式。例如，大腸膠囊內視鏡系統因其針對大腸評估的專門設計而備受青睞，而食道和小腸平台則針對特定的診斷場景。每個產品層級都展現出獨特的性能特徵，從針對食道轉運最佳化的膠囊尺寸到專為小腸成像設計的先進光學塗層。

重點介紹美洲、歐洲、中東和非洲以及亞太市場膠囊內視鏡應用的區域動態和市場促進因素

在美洲，尤其是北美市場，對胃腸道診斷基礎設施的投資正在加速膠囊內視鏡作為一種非侵入性檢查方式的普及。優惠的報銷政策和大腸直腸癌篩檢計畫的高普及率，促使臨床醫師將膠囊內視鏡系統納入常規診療方案。在拉丁美洲，不斷成長的醫療預算和公共衛生措施正在推動膠囊內視鏡的普及，儘管各國在成本考量和監管時間表方面存在差異。

在膠囊內視鏡市場格局不斷演變的背景下，與推動創新和策略合作的關鍵產業領導者會面

產業領導者以其技術力和策略夥伴關係關係旨在提升膠囊內視鏡的臨床效用。大型跨國公司正在大力投資高清影像增強和電池續航解決方案，並與研究機構合作，在同行評審研究中檢驗其貢獻。這些合作夥伴關係使得即時資料傳輸和整合立體定位感測器等設計功能的快速迭代成為可能，從而提高了手術效率和診斷準確性。

為行業領導者提供切實可行的建議，以提高技術部署的營運效率；監管合規性和市場定位策略

產業領導者應優先將人工智慧功能整合到膠囊內視鏡平台中，以提高病變檢測的準確性並縮短解讀時間。透過整合能夠自動標記異常的機器學習演算法，製造商可以提供全面的診斷工作流程，從而減輕臨床醫生的負擔並加快患者護理流程。同時，投資模組化設計原則和彈性製造可以幫助企業應對不斷變化的法規環境，並最大限度地減少供應鏈漏洞。

概述用於捕捉行業趨勢的調查方法；檢驗數據來源並對膠囊內視鏡市場洞察進行徹底分析

該研究結合了同行評審期刊、監管申報資料和臨床試驗資料庫的系統性綜述，以及對頂尖胃腸病學家、設備工程師和採購專家的深入訪談。嚴格的資訊來源三角檢定將定性見解與多個資料點進行交叉檢驗，增強了新興趨勢分析的可信度。二級資訊來源包括專業醫學協會的白皮書和監管機構發布的指南，為評估核准時間表和上市後監管要求提供了框架。

膠囊內視鏡在現代胃腸診斷中的演化整合和未來前景的總結性展望

隨著膠囊內視鏡技術的不斷發展，其對胃腸診斷的變革性影響日益顯著。從增強的超高解析度成像到遠端醫療平台內的無縫資料整合，這些可吞服的設備正在重新定義臨床醫生的工作流程和患者體驗。監管調整和合作研究舉措正在加速創新週期，推動從一次性膠囊到配備人工智慧和先進感測器的智慧系統的轉變。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

• 整合人工智慧演算法用於膠囊內視鏡系統中的即時病變檢測
• 可攜式膠囊內視鏡系統具有更長的電池壽命，可以延長小腸成像時間，而不會給患者帶來不適
• 全腸膠囊內視鏡的使用率正在不斷提高，它可以全面觀察從食道到大腸的消化道
• 開發可生物分解的膠囊內視鏡，最大限度地減少回收需求並降低環境影響
• 將膠囊內視鏡數據與遠端醫療和雲端分析平台相結合的遠端患者監護解決方案的成長
• 具有高解析度成像能力以及 pH、壓力和溫度測量能力的多感測器膠囊的進展
• 透過胃腸病學家和設備製造商之間的合作，實現膠囊內視鏡檢查報告和解釋通訊協定的標準化

第6章 市場洞察

• 波特五力分析
• PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：膠囊內視鏡市場（依產品類型）

• 結腸膠囊內視鏡檢查
• 食道膠囊內視鏡檢查
• 小腸膠囊內視鏡檢查

第9章膠囊內視鏡市場：內視鏡模式

• 可重複使用的膠囊
• 免洗膠囊

第 10 章膠囊內視鏡市場（依年齡層）

• 成人
• 老年人
• 孩子們

第11章膠囊內視鏡市場的應用

• 乳糜瀉
• 大腸癌篩檢
• 克隆氏症
• 胃食道逆流症
• 不明原因消化道出血（OGIB）
• 小腸腫瘤
• 潰瘍檢測

第12章膠囊內視鏡市場按分銷管道

• 離線
• 線上

第13章膠囊內視鏡市場（依最終用戶）

• 門診手術中心（ASC）
• 診斷中心
• 醫院
• 研究所

第 14 章：美洲膠囊內視鏡市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

15. 歐洲、中東和非洲膠囊內視鏡市場

• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 阿拉伯聯合大公國
• 沙烏地阿拉伯
• 南非
• 丹麥
• 荷蘭
• 卡達
• 芬蘭
• 瑞典
• 奈及利亞
• 埃及
• 土耳其
• 以色列
• 挪威
• 波蘭
• 瑞士

16. 亞太膠囊內視鏡市場

• 中國
• 印度
• 日本
• 澳洲
• 韓國
• 印尼
• 泰國
• 菲律賓
• 馬來西亞
• 新加坡
• 越南
• 台灣

第17章競爭格局

• 2024年市場佔有率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • Advin Health Care
  • Anx Robotica Corp.
  • Beijing Richen-Force Science & Technology Co.,Ltd
  • Biocam Sp. z oo
  • CapsoVision, Inc.
  • Covestro AG
  • Duomed Group
  • Fujifilm Holding Corporation
  • Intromedic co., Ltd
  • JINSHAN Science & Technology（Group）Co., Ltd.
  • Medtronic PLC
  • MU Ltd.
  • Olympus Corporation
  • RF Systems Lab
  • Shangxian Minimal Invasive Inc
  • STERIS
  • SynMed Ltd.

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

The Capsule Endoscopy Market was valued at USD 502.12 million in 2024 and is projected to grow to USD 541.09 million in 2025, with a CAGR of 8.01%, reaching USD 797.39 million by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 502.12 million
Estimated Year [2025]	USD 541.09 million
Forecast Year [2030]	USD 797.39 million
CAGR (%)	8.01%

Exploring the Transformative Role of Capsule Endoscopy Technologies in Redefining Noninvasive Gastrointestinal Diagnostics for Enhanced Patient Outcomes

Capsule endoscopy represents a landmark innovation in gastrointestinal diagnostics by replacing traditional invasive endoscopic procedures with a single swallowable device. The discreet nature of the capsule, equipped with high-definition imaging sensors, offers clinicians unrivaled access to deep sections of the small intestine that were previously challenging to visualize. As a result, patients experience reduced discomfort and risk compared to conventional endoscopy, fostering higher compliance rates among individuals requiring regular gastrointestinal assessment.

Initial trials and subsequent clinical adoption have underscored the value of this technology in detecting a spectrum of conditions, ranging from obscure gastrointestinal bleeding to suspected small intestine tumors. Enhanced illumination systems and expanded battery life have significantly increased the diagnostic yield, allowing longer transit durations and continuous image capture throughout the digestive tract. Coupled with wireless data acquisition platforms, these improvements have streamlined workflow for medical teams while offering real-time insights into patient health.

Looking ahead, ongoing research is focused on integrating advanced analytics and artificial intelligence into the capsule endoscopy framework. By leveraging machine learning algorithms to flag potential anomalies and cross-reference patient histories, the next generation of capsule endoscopy promises both heightened accuracy and accelerated reporting. This evolution underscores the critical role of capsule endoscopy in shaping future standards for noninvasive gastrointestinal care

Identifying Major Technological and Regulatory Shifts Shaping the Capsule Endoscopy Landscape and Driving Innovation in Gastrointestinal Imaging Worldwide

Technological breakthroughs have catalyzed an unparalleled transformation in the capsule endoscopy landscape, blurring the lines between diagnostics and data-driven decision making. Recent introductions of ultra-high-resolution imaging chips have delivered unprecedented clarity, enabling the detection of minute mucosal lesions that would have previously gone unnoticed. Meanwhile, advancements in power management have extended capsule battery life, permitting extended transit through the gastrointestinal tract and ensuring comprehensive visualization from the esophagus to the colon.

Simultaneously, regulatory frameworks have evolved to accommodate the growing complexity of ingestible diagnostic devices. Medical agencies across key markets have introduced expedited pathways for novel capsule designs and enhanced post-market surveillance protocols. These regulatory shifts have encouraged manufacturers to innovate aggressively while maintaining rigorous safety and efficacy standards. Consequently, the market has witnessed a surge in clinical collaborations aimed at validating new imaging modalities, including optical coherence tomography and hyperspectral analysis, within a capsule format.

In parallel, the convergence of telemedicine platforms and remote patient monitoring tools has redefined the patient experience. Physicians can now review capsule imagery in real time, and patients benefit from streamlined pre-procedure instructions and post-procedure consultations without in-person visits. These transformative shifts underscore an industry moving rapidly toward integrated care models, where capsule endoscopy functions not only as a diagnostic instrument but also as a key element in a broader digital health ecosystem

Evaluating the Cumulative Effects of the 2025 United States Tariff Adjustments on Global Capsule Endoscopy Supply Chains and Market Dynamics

In 2025, the imposition of updated United States tariffs has introduced a new set of challenges for the capsule endoscopy supply chain, prompting stakeholders to reevaluate sourcing strategies and cost structures. Historically reliant on components imported from major manufacturing hubs, device producers are now navigating elevated duties on specialized imaging sensors, microbattery units, and wireless transmission modules. As a result, production costs have risen, compelling manufacturers to explore alternative suppliers and form strategic partnerships to mitigate tariff-induced price pressures.

Moreover, these tariff adjustments have created ripple effects across distribution networks, with importers and healthcare providers facing higher acquisition expenses. Many hospitals and diagnostic centers have responded by renegotiating procurement agreements and seeking volume-based pricing arrangements to preserve budgetary margins. In tandem, suppliers are investing in domestic assembly capabilities and localized manufacturing initiatives to offset the financial impact of cross-border trade barriers. These activities have fostered greater supply chain resilience and have accelerated the implementation of nearshore production models.

Looking forward, industry participants are also advocating for policy dialogues to balance trade objectives with healthcare affordability. While tariffs aim to bolster domestic industrial growth, the ultimate concern remains the accessibility and pricing of life-saving diagnostic technologies. Stakeholders are therefore engaging with policymakers and trade associations to ensure that tariff frameworks evolve in a manner that sustains innovation while protecting patient access to advanced gastrointestinal diagnostics

Unveiling Critical Segmentation Insights for Product Variants Endoscopy Modes Age Groups Clinical Applications Distribution Channels and End User Categories

An in-depth segmentation analysis reveals distinct patterns in how different product configurations and clinical contexts shape market uptake. For instance, colon capsule endoscopy systems have gained prominence due to their targeted design for colorectal evaluation, while esophageal and small bowel platforms address specialized diagnostic scenarios. Each product tier demonstrates unique performance attributes, from capsule dimensions optimized for esophageal transit to advanced optical coatings engineered for small-bowel imaging.

Equally important is the differentiation by endoscopy mode, where reusable capsules are preferred for high-volume diagnostic centers seeking cost efficiencies, and single-use models appeal to institutions prioritizing sterility and patient safety. Age demographics further refine this picture, with adult patients representing the core user base, geriatric cohorts demanding minimally invasive options due to comorbidities, and pediatric applications driving innovation in capsule miniaturization.

Clinical applications present another layer of granularity, as the technology is employed for celiac disease monitoring, colon cancer screening, Crohn's disease assessment, gastroesophageal reflux evaluation, obscure gastrointestinal bleeding investigation, small intestine tumor detection, and precise ulcer identification. Distribution channels vary from established offline networks encompassing medical device distributors to emerging online portals that facilitate direct procurement. Finally, end users span ambulatory surgical centers seeking streamlined workflows, diagnostic centers focused on outpatient throughput, hospitals integrating capsule endoscopy into broader GI service lines, and research institutes exploring next-generation functionalities

Highlighting Regional Dynamics and Growth Drivers for Capsule Endoscopy Adoption across the Americas Europe Middle East Africa and Asia Pacific Markets

Across the Americas, particularly in North American markets, investment in gastrointestinal diagnostic infrastructure has accelerated the adoption of capsule endoscopy as a preferred noninvasive option. Favorable reimbursement policies and a high prevalence of colorectal cancer screening programs have driven clinicians to incorporate capsule systems into routine protocols. In Latin America, growing healthcare budgets and public health initiatives are fostering incremental uptake, although cost considerations and regulatory timelines vary by country.

Within Europe, the Middle East and Africa region, heterogeneous reimbursement landscapes pose both opportunities and challenges. Western European nations benefit from well-established reimbursement codes and robust clinical guidelines, which have enabled consistent integration of capsule endoscopy into gastroenterology practices. Conversely, parts of the Middle East are characterized by rapid modernization of healthcare facilities, leading to significant adoption surges in urban centers, while certain African markets remain constrained by limited specialist availability and infrastructure gaps.

The Asia-Pacific market exhibits dynamic growth driven by expanding healthcare access and rising awareness of digestive health issues. Countries such as Japan and South Korea, with advanced manufacturing capabilities and supportive regulatory frameworks, continue to lead in capsule endoscopy innovation. Meanwhile, emerging economies in Southeast Asia and India are witnessing increased demand for cost-effective, noninvasive diagnostic modalities, fueled by public screening campaigns and telemedicine integration. These regional dynamics underscore the importance of tailored market entry and engagement strategies

Showcasing Key Industry Leaders Driving Innovation and Strategic Collaborations in the Evolving Capsule Endoscopy Market Landscape

Industry leaders have distinguished themselves through a blend of technological prowess and strategic partnerships aimed at advancing the clinical utility of capsule endoscopy. Major multinational corporations have invested heavily in high-definition imaging enhancements and extended battery solutions, collaborating with research institutions to validate their contributions in peer-reviewed studies. These alliances have enabled rapid iteration of design features, such as real-time data transmission and integrated localization sensors, which enhance procedural efficiency and diagnostic accuracy.

Mid-tier manufacturers have likewise carved out specialized niches by focusing on cost-effective capsule platforms optimized for specific clinical segments, including pediatric applications and outpatient screening programs. These companies often leverage modular production frameworks to respond swiftly to evolving regulatory requirements and customer feedback. Collaborative agreements with hospitals and diagnostic clinics have facilitated field trials, enabling iterative refinement of software algorithms that support lesion detection and report generation.

In addition to hardware innovation, several key players have formed ecosystem partnerships with telehealth providers and cloud service operators to deliver end-to-end diagnostic solutions. This trend underscores a shift toward value-based care models, where capsule endoscopy emerges as a central component of integrated gastrointestinal health management. Collectively, these strategic activities reflect a competitive landscape where agility, clinical validation, and cross-sector collaborations define market leadership

Actionable Recommendations for Industry Leaders to Enhance Technological Adoption Operational Efficiency Regulatory Compliance and Market Positioning Strategies

Industry leaders should prioritize the integration of artificial intelligence capabilities into their capsule endoscopy platforms to enhance lesion detection accuracy and reduce interpretation times. By embedding machine learning algorithms capable of automated anomaly flagging, manufacturers can offer comprehensive diagnostic workflows that alleviate clinician burden and expedite patient care pathways. In parallel, investment in modular design principles and flexible manufacturing arrangements will help companies navigate evolving regulatory environments and minimize supply chain vulnerabilities.

Strategic partnerships with both domestic and nearshore component suppliers can mitigate the financial impact of cross-border tariffs while supporting more resilient production networks. Engaging proactively with regulatory agencies to secure expedited review pathways will further accelerate time-to-market for next-generation systems. In terms of market expansion, targeting emerging regions through customized reimbursement models and training programs can unlock new user bases, particularly in underserved areas where gastrointestinal conditions impose significant healthcare burdens.

Finally, healthcare providers and device developers alike should cultivate collaborative networks with telemedicine and digital health service providers. Offering integrated diagnostic packages that combine capsule endoscopy with remote patient monitoring and virtual follow-up consultations will align with broader value-based care initiatives. These actionable strategies will empower stakeholders to optimize diagnostic performance, reinforce market positioning, and deliver superior patient outcomes

Outlining the Research Methodology Employed to Capture Industry Trends Validate Data Sources and Ensure Thorough Analysis of Capsule Endoscopy Market Insights

This research effort combined a systematic review of peer-reviewed journals, regulatory filings, and clinical trial databases with in-depth interviews conducted with leading gastroenterologists, device engineers, and procurement specialists. Rigorous source triangulation ensured that qualitative insights were cross-validated against multiple data points, enhancing the reliability of emerging trend analysis. Secondary sources included white papers from professional medical societies and guidelines published by regulatory agencies, which provided a framework for assessing approval timelines and post-market surveillance requirements.

Primary research involved structured discussions with senior clinicians who have pioneered capsule endoscopy adoption in diverse clinical settings, alongside conversations with technical experts responsible for device design and integration. Feedback from procurement teams across ambulatory centers and hospitals shed light on distribution channel dynamics and purchasing decision criteria. All insights were synthesized through a multi-stage analytical process, which encompassed thematic coding to identify core drivers, barriers, and innovation hotspots. These findings were then subjected to peer review by an experienced advisory panel to ensure comprehensive coverage and unbiased interpretation. Through this methodology, the study delivers a robust and nuanced understanding of the capsule endoscopy ecosystem

Drawing Conclusive Perspectives on the Evolution Integration and Future Outlook of Capsule Endoscopy in Modern Gastrointestinal Diagnostics

As capsule endoscopy technologies continue to evolve, their transformative impact on gastrointestinal diagnostics is becoming increasingly evident. From ultra-high-resolution imaging enhancements to seamless data integration within telehealth platforms, these ingestible devices are redefining clinician workflows and patient experiences alike. Regulatory adaptations and collaborative research initiatives have accelerated innovation cycles, driving the transition from single-use capsules toward intelligent systems powered by artificial intelligence and advanced sensor modalities.

The cumulative effect of U.S. tariff adjustments in 2025 highlights the importance of resilient supply chain strategies and nearshore manufacturing capabilities. Meanwhile, segmentation analysis underscores distinct preferences among clinical applications, age groups, and endoscopy modes, offering manufacturers opportunities to tailor solutions to specific market niches. Regional dynamics in the Americas, EMEA, and Asia-Pacific further illustrate the necessity of localized approaches that consider reimbursement landscapes, infrastructure maturity, and patient awareness levels.

Looking ahead, stakeholders who embrace modular design, foster strategic ecosystem partnerships, and prioritize regulatory alignment will be best positioned to capture the next wave of growth. The evolution of capsule endoscopy is not simply a technological journey, but a paradigm shift toward patient-centric, data-driven healthcare. As this field matures, it will play an integral role in holistic gastrointestinal care pathways, empowering clinicians with tools that deliver precision, efficiency, and enhanced patient outcomes

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Integration of artificial intelligence algorithms for real-time lesion detection in capsule endoscopy systems
• 5.2. Portable capsule endoscopy systems with enhanced battery life enabling extended small bowel imaging sessions without patient discomfort
• 5.3. Emerging adoption of pan-intestinal capsule scopes for comprehensive GI tract visualization from esophagus to colon
• 5.4. Development of biodegradable capsule endoscopes minimizing retrieval requirements and reducing environmental impact
• 5.5. Growth in remote patient monitoring solutions integrating capsule endoscopy data with telehealth and cloud analytics platforms
• 5.6. Advances in multi-sensor capsules offering pH pressure and temperature measurements alongside high resolution imaging capabilities
• 5.7. Collaboration between gastroenterologists and device manufacturers to standardize capsule endoscopy reporting and interpretation protocols

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Capsule Endoscopy Market, by Product Type

• 8.1. Introduction
• 8.2. Colon Capsule Endoscopy
• 8.3. Esophageal Capsule Endoscopy
• 8.4. Small Bowel Capsule Endoscopy

9. Capsule Endoscopy Market, by Endoscopy Mode

• 9.1. Introduction
• 9.2. Reusable Capsules
• 9.3. Single Use Capsules

10. Capsule Endoscopy Market, by Age Group

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric
• 10.4. Pediatric

11. Capsule Endoscopy Market, by Application

• 11.1. Introduction
• 11.2. Celiac Disease
• 11.3. Colon Cancer Screening
• 11.4. Crohn's Disease
• 11.5. Gastroesophageal Reflux Disease
• 11.6. Obscure Gastrointestinal Bleeding (OGIB)
• 11.7. Small Intestine Tumors
• 11.8. Ulcer Detection

12. Capsule Endoscopy Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Capsule Endoscopy Market, by End User

• 13.1. Introduction
• 13.2. Ambulatory Surgical Centers (ASCs)
• 13.3. Diagnostic Centers
• 13.4. Hospitals
• 13.5. Research Institutes

14. Americas Capsule Endoscopy Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Capsule Endoscopy Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Capsule Endoscopy Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Advin Health Care
  • 17.3.2. Anx Robotica Corp.
  • 17.3.3. Beijing Richen-Force Science & Technology Co.,Ltd
  • 17.3.4. Biocam Sp. z o.o.
  • 17.3.5. CapsoVision, Inc.
  • 17.3.6. Covestro AG
  • 17.3.7. Duomed Group
  • 17.3.8. Fujifilm Holding Corporation
  • 17.3.9. Intromedic co., Ltd
  • 17.3.10. JINSHAN Science & Technology (Group) Co., Ltd.
  • 17.3.11. Medtronic PLC
  • 17.3.12. MU Ltd.
  • 17.3.13. Olympus Corporation
  • 17.3.14. RF Systems Lab
  • 17.3.15. Shangxian Minimal Invasive Inc
  • 17.3.16. STERIS
  • 17.3.17. SynMed Ltd.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix